Silexion Therapeutics Corp (SLXN)

$2.59 -0.02 (-0.77%)
Market Cap 1.09M
Revenue (ttm) 0.00
Net Income (ttm) -11.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 14,600
Avg Vol 790,686
Day's Range N/A - N/A
Shares Out 419,000.00
Stochastic %K 26%
Beta -0.26
Analysts Strong Sell
Price Target $60.00

Company Profile

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatmen...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 2 674 3430
Fax: 972 2 643 0982
Address:
The Goldyne Savad Inst. of Gene Therapy, Hadassah Hebrew Univ Medical Ctr, Jerusalem, Israel
Bear_Police
Bear_Police Jul. 10 at 5:29 PM
$SLXN Am I the only regard here with shares!? Dont be asking later on how do people find this stocks that goes 500% 😂.. This is how! You get bored just holding till its 500% . Lol
0 · Reply
ZacksResearch
ZacksResearch Jul. 6 at 1:28 PM
After a 47% plunge, is $SLXN a bargain… or a value trap? 🤔 📉 Shares have fallen 47% in the past month. 📊 The stock trades at a 12-month trailing P/B of 3.81, above the industry average of 3.67, but still below its 5-year mean of 5.83. 🔍 Loss estimates for 2026 have remained unchanged at $45.50 over the past 30 days, suggesting analyst expectations have stabilized. See what Wall Street analysts recommend 👉 https://www.zacks.com/stock/research/SLXN/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-38639&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_38639
0 · Reply
Bear_Police
Bear_Police Jul. 2 at 2:17 PM
$SLXN One positive catalysts we go boom!
0 · Reply
Sauceg
Sauceg Jun. 30 at 3:48 PM
$SLXN this scam still here lol stay away yall
0 · Reply
mcluca
mcluca Jun. 26 at 8:25 PM
$SLXN will break trought to $7 next week
0 · Reply
Bear_Police
Bear_Police Jun. 26 at 4:47 PM
$SLXN oh! Going in the right direction
0 · Reply
mcluca
mcluca Jun. 26 at 4:05 PM
$SLXN 👀
0 · Reply
Bear_Police
Bear_Police Jun. 25 at 8:26 PM
$SLXN Just waiting to get paid!
0 · Reply
Bear_Police
Bear_Police Jun. 24 at 4:47 PM
$SLXN That convention ends today hopefully some more good news eow!
0 · Reply
Golden_Cross
Golden_Cross Jun. 24 at 3:33 PM
$SLXN Targeting $5+
0 · Reply
Latest News on SLXN
Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Jun 23, 2026, 8:40 AM EDT - 17 days ago

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Silexion Therapeutics to Attend BIO International Convention 2026

Jun 16, 2026, 4:30 PM EDT - 24 days ago

Silexion Therapeutics to Attend BIO International Convention 2026

Silexion Therapeutics files to sell 859,609 ordinary shares for holders

2026-06-12T20:10:49.000Z - 4 weeks ago

Silexion Therapeutics files to sell 859,609 ordinary shares for holders

Silexion Therapeutics Corp trading halted, news pending

2026-05-28T23:50:59.000Z - 6 weeks ago

Silexion Therapeutics Corp trading halted, news pending

Silexion Therapeutics announces 1-for-10 reverse share split

2026-05-26T14:30:18.000Z - 6 weeks ago

Silexion Therapeutics announces 1-for-10 reverse share split

Silexion Therapeutics Announces 1-for-10 Reverse Share Split

May 26, 2026, 8:30 AM EDT - 6 weeks ago

Silexion Therapeutics Announces 1-for-10 Reverse Share Split

3 Penny Stocks to Watch Now, 5/21/26

2026-05-21T19:20:55.000Z - 7 weeks ago

3 Penny Stocks to Watch Now, 5/21/26

HCWB MTVA

Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 18, 2026, 8:30 AM EDT - 7 weeks ago

Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds

May 15, 2026, 8:27 AM EDT - 2 months ago

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds

Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer

May 14, 2026, 9:27 AM EDT - 2 months ago

Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer

Silexion Therapeutics initiates GMP clinical batch manufacturing of SIL204

2026-05-13T16:35:51.000Z - 2 months ago

Silexion Therapeutics initiates GMP clinical batch manufacturing of SIL204

Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center

May 13, 2026, 8:00 AM EDT - 2 months ago

Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center

Silexion Therapeutics submits SIL204 clinical trial application to Germany

2026-04-28T14:13:48.000Z - 2 months ago

Silexion Therapeutics submits SIL204 clinical trial application to Germany

Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany's BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer

Apr 28, 2026, 8:45 AM EDT - 2 months ago

Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany's BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer

Silexion Therapeutics approved to initiate Phase 2/3 clinical trial of SIL204

2026-03-24T13:50:15.000Z - 3 months ago

Silexion Therapeutics approved to initiate Phase 2/3 clinical trial of SIL204

Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Mar 24, 2026, 9:46 AM EDT - 3 months ago

Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 17, 2026, 5:01 PM EDT - 4 months ago

Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Silexion Therapeutics urges shareholders to vote ahead of EGM

2026-03-05T13:22:21.000Z - 4 months ago

Silexion Therapeutics urges shareholders to vote ahead of EGM

Silexion Therapeutics issues letter to shareholders

2026-01-06T12:40:28.000Z - 6 months ago

Silexion Therapeutics issues letter to shareholders

Silexion submits Phase 2/3 trial application to Israel for SIL204

2025-12-16T13:45:35.000Z - 7 months ago

Silexion submits Phase 2/3 trial application to Israel for SIL204

Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer

Dec 16, 2025, 8:40 AM EST - 7 months ago

Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer

Silexion Therapeutics initiated with a Buy at Litchfield Hills

2025-12-15T13:00:43.000Z - 7 months ago

Silexion Therapeutics initiated with a Buy at Litchfield Hills

Silexion receives positive feedback from German Health Authority for SIL204

2025-12-02T13:10:13.000Z - 7 months ago

Silexion receives positive feedback from German Health Authority for SIL204

Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

Nov 26, 2025, 7:30 AM EST - 8 months ago

Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

Silexion Therapeutics completes toxicology studies for SIL204

2025-11-25T14:20:40.000Z - 8 months ago

Silexion Therapeutics completes toxicology studies for SIL204

Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer

Nov 25, 2025, 9:15 AM EST - 8 months ago

Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer

Silexion Therapeutics reports Q3 EPS $2.88 vs $274.25 last year

2025-11-12T14:06:19.000Z - 8 months ago

Silexion Therapeutics reports Q3 EPS $2.88 vs $274.25 last year

Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 9:00 AM EST - 8 months ago

Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Silexion Therapeutics files to sell 1.29M ordinary shares for holders

2025-10-31T21:10:10.000Z - 9 months ago

Silexion Therapeutics files to sell 1.29M ordinary shares for holders

Silexion Therapeutics announces new data in SIL204

2025-09-30T12:50:48.000Z - 10 months ago

Silexion Therapeutics announces new data in SIL204

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

Sep 30, 2025, 8:40 AM EDT - 10 months ago

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

Silexion Therapeutics files $100M mixed securities shelf

2025-09-26T20:35:21.000Z - 10 months ago

Silexion Therapeutics files $100M mixed securities shelf

Silexion Therapeutics regains compliance with Nasdaq listing requirements

2025-09-25T12:50:46.000Z - 10 months ago

Silexion Therapeutics regains compliance with Nasdaq listing requirements

Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements

Sep 25, 2025, 8:45 AM EDT - 10 months ago

Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements

Silexion Therapeutics prices 1.5M shares at $4.00 in public offering

2025-09-11T13:25:36.000Z - 10 months ago

Silexion Therapeutics prices 1.5M shares at $4.00 in public offering

Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering

Sep 11, 2025, 9:17 AM EDT - 10 months ago

Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

Sep 11, 2025, 7:00 AM EDT - 10 months ago

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204

Sep 4, 2025, 9:25 AM EDT - 11 months ago

Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Sep 2, 2025, 8:45 AM EDT - 11 months ago

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 12, 2025, 8:00 AM EDT - 11 months ago

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

Jul 31, 2025, 8:00 PM EDT - 1 year ago

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation

Jul 31, 2025, 9:55 AM EDT - 1 year ago

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

Jul 16, 2025, 8:44 AM EDT - 1 year ago

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines

Jul 9, 2025, 8:30 AM EDT - 1 year ago

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines

PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment

May 22, 2025, 3:46 PM EDT - 1 year ago

PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer

May 21, 2025, 8:45 AM EDT - 1 year ago

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:45 PM EDT - 1 year ago

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

Apr 23, 2025, 9:20 AM EDT - 1 year ago

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Mar 21, 2025, 8:30 AM EDT - 1 year ago

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Mar 18, 2025, 4:29 PM EDT - 1 year ago

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Mar 17, 2025, 8:15 AM EDT - 1 year ago

PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

Mar 5, 2025, 8:30 AM EST - 1 year ago

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Mar 3, 2025, 8:30 AM EST - 1 year ago

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Feb 25, 2025, 8:30 AM EST - 1 year ago

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

Jan 29, 2025, 5:30 PM EST - 1 year ago

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

PESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Jan 29, 2025, 9:59 AM EST - 1 year ago

PESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Jan 28, 2025, 8:29 AM EST - 1 year ago

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

PESG Market Update: Silexion Therapeutics' SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Jan 16, 2025, 11:04 AM EST - 1 year ago

PESG Market Update: Silexion Therapeutics' SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Jan 15, 2025, 8:00 PM EST - 1 year ago

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Jan 15, 2025, 4:01 PM EST - 1 year ago

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

Jan 13, 2025, 7:50 AM EST - 1 year ago

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

Dec 17, 2024, 9:36 AM EST - 1 year ago

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

AMGN

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

Nov 22, 2024, 4:30 PM EST - 1 year ago

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

Nov 20, 2024, 8:30 AM EST - 1 year ago

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

Oct 1, 2024, 6:45 AM EDT - 1 year ago

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

Sep 24, 2024, 7:30 AM EDT - 1 year ago

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Sep 9, 2024, 7:32 AM EDT - 1 year ago

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference

Sep 3, 2024, 4:05 PM EDT - 2 years ago

Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference

Bear_Police
Bear_Police Jul. 10 at 5:29 PM
$SLXN Am I the only regard here with shares!? Dont be asking later on how do people find this stocks that goes 500% 😂.. This is how! You get bored just holding till its 500% . Lol
0 · Reply
ZacksResearch
ZacksResearch Jul. 6 at 1:28 PM
After a 47% plunge, is $SLXN a bargain… or a value trap? 🤔 📉 Shares have fallen 47% in the past month. 📊 The stock trades at a 12-month trailing P/B of 3.81, above the industry average of 3.67, but still below its 5-year mean of 5.83. 🔍 Loss estimates for 2026 have remained unchanged at $45.50 over the past 30 days, suggesting analyst expectations have stabilized. See what Wall Street analysts recommend 👉 https://www.zacks.com/stock/research/SLXN/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-38639&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_38639
0 · Reply
Bear_Police
Bear_Police Jul. 2 at 2:17 PM
$SLXN One positive catalysts we go boom!
0 · Reply
Sauceg
Sauceg Jun. 30 at 3:48 PM
$SLXN this scam still here lol stay away yall
0 · Reply
mcluca
mcluca Jun. 26 at 8:25 PM
$SLXN will break trought to $7 next week
0 · Reply
Bear_Police
Bear_Police Jun. 26 at 4:47 PM
$SLXN oh! Going in the right direction
0 · Reply
mcluca
mcluca Jun. 26 at 4:05 PM
$SLXN 👀
0 · Reply
Bear_Police
Bear_Police Jun. 25 at 8:26 PM
$SLXN Just waiting to get paid!
0 · Reply
Bear_Police
Bear_Police Jun. 24 at 4:47 PM
$SLXN That convention ends today hopefully some more good news eow!
0 · Reply
Golden_Cross
Golden_Cross Jun. 24 at 3:33 PM
$SLXN Targeting $5+
0 · Reply
BOGGLE69
BOGGLE69 Jun. 24 at 3:23 PM
$SLXN grabbed a few.
0 · Reply
Golden_Cross
Golden_Cross Jun. 24 at 3:20 PM
$SLXN Loading here!
0 · Reply
lewisnelmes18
lewisnelmes18 Jun. 24 at 3:16 PM
$SLXN slapped run it up $3
0 · Reply
Golden_Cross
Golden_Cross Jun. 24 at 3:10 PM
$SLXN Short squeeze coming!
0 · Reply
MrTicker
MrTicker Jun. 23 at 8:02 PM
$SLXN Form SCHEDULE 13D/A Silexion Therapeutics Filed by: Moringa Sponsor, LP 10K WIZARD 3:00 PM ET 6/23/2026 http://archive.fast-edgar.com/20260623/A722522CLZ22S29222ZT22Y2O7PGW222E286 Filed on: June 23, 2026
1 · Reply
MrTicker
MrTicker Jun. 23 at 4:00 PM
$SLXN solid new today. afternoon warm-up starting to get some scanner attention. Need more volume to break $3 and hold on the 5 min for more continued upside.
1 · Reply
Bulllllllllllllllllllll
Bulllllllllllllllllllll Jun. 23 at 2:33 PM
$SLXN
0 · Reply
Bulllllllllllllllllllll
Bulllllllllllllllllllll Jun. 23 at 1:59 PM
$SLXN This will execute even higher. Enter early. Below $3 is a future.
0 · Reply
Iiontamer
Iiontamer Jun. 23 at 1:40 PM
$SLXN only question left now is will the shorts get this under $1 today or by the end of the week. Today’s news is absolutely useless as it shows the next worthy news item is probably months away
0 · Reply
ZacksResearch
ZacksResearch Jun. 23 at 1:36 PM
$SLXN just cleared a regulatory hurdle in pancreatic cancer 🚀 ✅ Germany's BfArM approved initiation of its Phase 2/3 pancreatic cancer trial of SIL204 without conditions 🌍 Regulatory approvals are now secured in both Germany and Israel 🩺 First patient dosing is expected in the coming weeks, pending final site activation procedures How to play the stock? Should you buy sell or hold? See what Wall Street analysts recommend 👉 https://www.zacks.com/stock/research/SLXN/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-38486&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_38486
1 · Reply
MrTicker
MrTicker Jun. 23 at 1:36 PM
$SLXN Silexion Therapeutics Says Germany Approves Phase 2/3 Trial of SIL204 in Pancreatic Cancer MT NEWSWIRES 8:31 AM ET 6/23/2026
0 · Reply